ESPR | Ticker Profile - Titan Protect

ESPR

Esperion Therapeutics, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NGM

$3.13

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$806M

Total market value of the company

Trailing P/E

N/A

Forward P/E

10.72

Based on estimated future earnings — lower means cheaper

Rev Growth

+23.2%

Year-over-year revenue change

Profit Margin

-1.8%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.16

+1% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

https://www.esperion.com

Country: United States Employees: 294 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.628

Good returns relative to risk taken

Kelly Fraction

-0.0041

No positive edge detected — the data suggests staying out

Calmar Ratio

0.250

Drawdown risk outweighs the returns — higher risk profile

Annual Return

20.2%

Historical annualised return based on price data

Max Drawdown

-80.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.91

Less volatile than the market — more defensive

52W High

$4.18

25% below the year high

52W Low

$0.81

286% above the year low

Avg Volume

11,510,981

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

8.0%

Moderate short interest

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

1.53

Healthy liquidity position

Quick Ratio

0.96

Like current ratio but excludes inventory — stricter test

Gross Margin

57.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-8.2%

Profit from core operations before interest and tax

Free Cash Flow

$-49,706,376

Negative — the business is spending more than it generates

Revenue (TTM)

$418M

Total revenue over the last 12 months

Net Income

$-7,423,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.28

Target Median

$3.16

Target Low

$3.16

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go